BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 23590380)

  • 1. A case of pyoderma gangrenosum possibly associated with sunitinib treatment.
    Ueharaguchi Y; Kabashima K; Sasahashi M; Matsuda A; Matubara K; Matsui M
    Int J Dermatol; 2013 May; 52(5):634-6. PubMed ID: 23590380
    [No Abstract]   [Full Text] [Related]  

  • 2. Pyoderma gangrenosum with the use of sunitinib.
    Nadauld LD; Miller MB; Srinivas S
    J Clin Oncol; 2011 Apr; 29(10):e266-7. PubMed ID: 21220606
    [No Abstract]   [Full Text] [Related]  

  • 3. [Sunitinib-induced pyoderma gangrenosum].
    Schmutz JL; Trechot P
    Ann Dermatol Venereol; 2013 Dec; 140(12):841-2. PubMed ID: 24315238
    [No Abstract]   [Full Text] [Related]  

  • 4. Imatinib induced pyoderma gangrenosum.
    Pinato DJ; Sharma R
    J Postgrad Med; 2013; 59(3):244-5. PubMed ID: 24029213
    [No Abstract]   [Full Text] [Related]  

  • 5. Eruptive melanocytic nevi in a patient undergoing treatment with sunitinib.
    Jiménez-Gallo D; Albarrán-Planelles C; Linares-Barrios M; Martínez-Rodríguez A; Báez-Perea JM
    JAMA Dermatol; 2013 May; 149(5):624-6. PubMed ID: 23677103
    [No Abstract]   [Full Text] [Related]  

  • 6. Pyoderma gangrenosum: another cutaneous side-effect of sunitinib?
    ten Freyhaus K; Homey B; Bieber T; Wilsmann-Theis D
    Br J Dermatol; 2008 Jul; 159(1):242-3. PubMed ID: 18489600
    [No Abstract]   [Full Text] [Related]  

  • 7. Palmar-plantar erythrodysesthesia secondary to sunitinib treatment resulting in necrotic foot syndrome aggravated by background diabetic vascular disease.
    Guenova E; Weber HO; Voykov B; Metzler G; Mitev V; Berneburg M; Hoetzenecker W; Röcken M
    Arch Dermatol; 2008 Aug; 144(8):1081-2. PubMed ID: 18711102
    [No Abstract]   [Full Text] [Related]  

  • 8. Sunitinib-induced subungual splinter haemorrhage and acral erythema.
    Nakamura M; Miyachi Y
    Eur J Dermatol; 2008; 18(3):344-5. PubMed ID: 18474471
    [No Abstract]   [Full Text] [Related]  

  • 9. Sunitinib-induced pyoderma gangrenosum-like skin ulcer.
    Kuntz T; Koushk-Jalali B; Kreuter A
    CMAJ; 2020 May; 192(20):E552. PubMed ID: 32452467
    [No Abstract]   [Full Text] [Related]  

  • 10. Pyoderma Gangrenosum Associated with Sunitinib: A Case Report.
    Sevimli Dikicier B
    Adv Skin Wound Care; 2019 Sep; 32(9):427-429. PubMed ID: 31408027
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sunitinib-induced thyrotoxicosis.
    Piñar D; Boix E; Meana JA; Herrero J
    J Endocrinol Invest; 2009 Dec; 32(11):941-2. PubMed ID: 19636224
    [No Abstract]   [Full Text] [Related]  

  • 12. Sunitinib induced pyoderma gangrenosum-like ulcerations.
    Akanay-Diesel S; Hoff NP; Kürle S; Haes J; Erhardt A; Häussinger D; Schulte KW; Bölke E; Matuschek C; Budach W; Gerber PA; Homey B
    Eur J Med Res; 2011 Nov; 16(11):491-4. PubMed ID: 22027642
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Skin depigmentation induced by sunitinib treatment of renal cell carcinoma.
    Al Enazi MM; Kadry R; Mitwali H
    J Am Acad Dermatol; 2009 Nov; 61(5):905-6. PubMed ID: 19836653
    [No Abstract]   [Full Text] [Related]  

  • 14. Acute cardiac failure after sunitinib.
    Machiels JP; Bletard N; Pirenne P; Jacquet L; Bonbled F; Duck L
    Ann Oncol; 2008 Mar; 19(3):597-9. PubMed ID: 18272908
    [No Abstract]   [Full Text] [Related]  

  • 15. Cardiac tamponade in a patient treated by sunitinib for metastatic renal cell carcinoma.
    Yıldız I; Varol U; Şen F; Kılıç L
    Anadolu Kardiyol Derg; 2014 Nov; 14(7):654-6. PubMed ID: 25163084
    [No Abstract]   [Full Text] [Related]  

  • 16. Re: Hypothyroidism in patients with metastatic renal cell carcinoma treated with sunitinib.
    Feldman DR; Martorella AJ; Robbins RJ; Motzer RJ
    J Natl Cancer Inst; 2007 Jun; 99(12):974-5; author reply 976-7. PubMed ID: 17565156
    [No Abstract]   [Full Text] [Related]  

  • 17. Pyoderma gangrenosum possibly triggered by adalimumab.
    Kikuchi N; Hiraiwa T; Ohashi T; Hanami Y; Satoh M; Takenoshita H; Yamamoto T
    Eur J Dermatol; 2012; 22(6):804-5. PubMed ID: 23107608
    [No Abstract]   [Full Text] [Related]  

  • 18. Response to 'Thyrotoxicosis during sunitinib treatment for renal cell carcinoma' by Grossmann et al.
    Daniels GH
    Clin Endocrinol (Oxf); 2009 Sep; 71(3):455. PubMed ID: 19138312
    [No Abstract]   [Full Text] [Related]  

  • 19. Re: Hypothyroidism in patients with metastatic renal cell carcinoma treated with sunitinib.
    Garfield DH; Hercbergs A; Davis PJ
    J Natl Cancer Inst; 2007 Jun; 99(12):975-6; author reply 976-7. PubMed ID: 17565154
    [No Abstract]   [Full Text] [Related]  

  • 20. Hand-foot syndrome and seborrheic dermatitis-like rash induced by sunitinib in a patient with advanced renal cell carcinoma.
    Tsai KY; Yang CH; Kuo TT; Hong HS; Chang JW
    J Clin Oncol; 2006 Dec; 24(36):5786-8. PubMed ID: 17179114
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.